Ipca Laboratories Peer Comparison

NSE: IPCALAB | BSE: 524494

₹1,943.20

₹16.20 (0.84%)

As on 01-Oct-2026IST

Market cap

₹49,216 Cr

Revenue (TTM)

₹10,126 Cr

P/E Ratio

37.6

P/B Ratio

5.8

Div. Yield

0.3 %

Edit

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Market cap (₹ Cr)	49,216	1,13,481	1,04,005	1,00,554	95,916
Revenue (₹ Cr)	10,126	28,592	14,738	33,228	34,935
Net Profit (₹ Cr)	1,379.76	4,492.20	2,055.11	3,169.30	3,712.74
Net Margin (%)	13.41	14.92	13.64	9.15	10.42
RoE (%)	17.72	18.78	13.60	8.72	10.38
Price to Earnings	37.58	25.15	50.92	31.21	25.84
Price-To-Book	5.80	4.21	6.18	2.63	2.46

Income Statement (₹ Cr)

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Operating Revenue	10,125.58	28,591.70	14,737.88	33,227.90	34,935.29
Total Income	10,292.63	30,111.40	15,061.79	34,650.70	35,624.79
Total Expenditure	7,893.93	21,334.70	10,911.05	28,088.10	27,850.01
EBITDA	2,231.65	7,257.00	3,826.83	5,139.80	7,085.28
Depreciation	428.87	1,724.60	893.20	2,119.30	1,859.31
EBIT	1,802.78	5,532.40	2,933.63	3,020.50	5,225.97
Interest	69.31	510.20	578.61	416.30	387.88
Other Income	167.05	1,519.70	323.91	1,422.80	689.50
Exceptional Items	-86.43	-534.80	-129.75	0.00	-105.51
Profit before Tax	1,814.09	6,007.10	2,549.18	4,027.00	5,422.08
Provision for Tax	434.33	1,514.90	494.07	857.70	1,709.34
Profit after Tax	1,379.76	4,492.20	2,055.11	3,169.30	3,712.74

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Shareholder's Funds	8,063.81	27,111.40	16,300.34	37,891.50	37,890.97
Minority Interest	-65.36	-79.70	-24.90	38.90	1.76
Non-Current Liabilities	539.20	7,112.50	5,011.23	3,145.10	2,580.33
Current Liabilities	2,306.93	15,711.90	6,507.25	16,747.40	18,039.01
Total Liabilities	12,349.65	50,672.60	27,754.83	56,576.70	58,196.15

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Non-Current Assets	5,384.61	31,677.20	20,274.65	27,204.00	24,040.45
Current Assets	6,373.61	19,906.10	6,954.20	30,179.30	32,708.75
Total Assets	12,349.65	50,672.60	27,754.83	56,576.70	58,196.15
Total Debt*	703.94	11,769.50	6,021.78	7,734.10	7,676.20
Net Current Assets	4,066.68	4,194.20	446.95	13,431.90	14,669.74
Contingent Liabilities	249.19	989.90	924.77	336.14	1,358.37

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Cash From Operating Activities	1,141.97	2,116.60	3,121.29	5,673.70	5,526.37
Cash Flow from Investing Activities	-246.77	-8,296.10	-196.42	-6,549.30	-3,458.61
Cash from Financing Activities	-753.53	5,806.90	-2,952.69	829.00	-1,269.15
Net Cash Inflow / Outflow	141.67	-372.60	-27.82	-46.60	798.61

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
ROCE (%)	19.41	21.39	13.24	13.75	12.76
ROE (%)	17.72	18.78	13.60	8.72	10.38
ROA (%)	11.44	10.03	7.36	5.89	6.86
EBIT Margin (%)	17.80	19.35	19.91	9.09	14.96
Net Margin (%)	13.41	14.92	13.64	9.15	10.42
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Revenue Growth (%)	10.59	21.11	14.16	-0.87	9.09
EBIT Growth (%)	33.46	-8.99	19.45	-55.06	6.91
Net Profit Growth (%)	67.66	-3.14	8.09	-44.66	8.63
EPS Growth (%)	54.72	4.31	12.27	-43.29	11.88
Book Value Growth (%)	16.05	13.19	13.74	12.99	16.04

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Price / Earnings	36.07	23.06	47.91	31.04	25.39
Price / Book Value	5.84	4.18	6.12	2.62	2.45
Dividend Yield (%)	0.31	0.09	0.04	0.67	0.24
EV/EBITDA	21.97	16.16	27.96	19.60	13.06
Market Cap (₹ Cr)	40,668.17	87,643.18	82,801.75	1,04,763.81	75,689.14

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Debt to Equity	0.01	0.12	0.17	0.00	0.02
Short term debt to equity ratio	0.05	0.16	0.04	0.16	0.16
Current Ratio	2.76	1.27	1.07	1.80	1.81
Quick Ratio	1.58	0.91	0.74	1.35	1.15
Interest Coverage	27.17	12.77	5.41	10.67	14.98

	Ipca Laboratories	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Debtors to sales (%)	19.89	18.94	11.74	30.47	20.31
Asset Turnover	0.84	0.64	0.53	0.62	0.65
Receivable days	73.75	33.55	39.93	103.79	33.71
Inventory Days	100.11	33.80	51.78	79.94	59.32
Payable days	131.14	149.82	111.46	84.78	148.20
Cash Conversion Cycle	42.73	-82.46	-19.75	98.95	-55.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.